EMILY BROADBENT: Open Payments
NPI 1447891155 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$453 in 15 payments from 11 companies in 2025. Trend: 2023 $593 · 2024 $226 · 2025 $453
Food & beverage: $453
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 1 | $135 |
| Genentech USA, Inc. | 3 | $73 |
| Novartis Pharmaceuticals Corporation | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| JAZZ PHARMACEUTICALS INC. | 1 | $29 |
| Incyte Corporation | 1 | $26 |
| Karyopharm Therapeutics Inc. | 1 | $21 |
| Deciphera Pharmaceuticals Inc. | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $17 |
Products named: RYBREVANT, Polivy, Fabhalta, Onivyde, Itovebi, ZEPZELCA, MONJUVI, XPOVIO.
Industry payments across DE — which companies pay providers there.
